lupus coagulation inhibitor

Summary

Summary: An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.

Top Publications

  1. pmc Antiphospholipid antibody tests: spreading the net
    M L Bertolaccini
    Lupus Research Unit, The Rayne Institute, St Thomas Hospital, London SE1 7EH, UK
    Ann Rheum Dis 64:1639-43. 2005
  2. ncbi Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy
    A Ruffatti
    Department of Clinical and Experimental Medicine, University of Padua, Italy
    Thromb Res 123:482-7. 2009
  3. pmc Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies
    Michael D Lockshin
    Hospital for Special Surgery and Weill Cornell Medical College, New York, New York
    Arthritis Rheum 64:2311-8. 2012
  4. ncbi Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
    V Pengo
    Clinical Cardiology, Thrombosis Center, University Hospital, Padova, Italy
    J Thromb Haemost 8:237-42. 2010
  5. ncbi Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification
    A Ruffatti
    Rheumatology Unit, University of Padua, Padua, Padova, Italy
    J Thromb Haemost 6:1693-6. 2008
  6. ncbi Invitation to a debate on the serological criteria that define the antiphospholipid syndrome
    M Galli
    J Thromb Haemost 6:399-401. 2008
  7. ncbi Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke
    T Kahles
    Department of Neurology, University Hospital, JW Goethe University Frankfurt, Germany
    Rheumatology (Oxford) 44:1161-5. 2005
  8. ncbi Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies
    C Chauleur
    Research Team EA2992, Montpellier University 1, Nimes, France
    J Thromb Haemost 8:699-706. 2010
  9. ncbi Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort
    M Petri
    Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland 21205, USA
    Lupus 19:419-23. 2010
  10. ncbi Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
    Monica Galli
    Division of Hematology, Ospedali Riuniti, Bergamo, Italy
    Blood 101:1827-32. 2003

Research Grants

Detail Information

Publications223 found, 100 shown here

  1. pmc Antiphospholipid antibody tests: spreading the net
    M L Bertolaccini
    Lupus Research Unit, The Rayne Institute, St Thomas Hospital, London SE1 7EH, UK
    Ann Rheum Dis 64:1639-43. 2005
    ....
  2. ncbi Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy
    A Ruffatti
    Department of Clinical and Experimental Medicine, University of Padua, Italy
    Thromb Res 123:482-7. 2009
    ..A relationship between antibody profile and pregnancy outcome in patients with a previous diagnosis of primary antiphospholipid syndrome (APS) has not been clearly documented...
  3. pmc Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies
    Michael D Lockshin
    Hospital for Special Surgery and Weill Cornell Medical College, New York, New York
    Arthritis Rheum 64:2311-8. 2012
    ....
  4. ncbi Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
    V Pengo
    Clinical Cardiology, Thrombosis Center, University Hospital, Padova, Italy
    J Thromb Haemost 8:237-42. 2010
    ..The characteristics and the clinical course of antiphospholipid syndrome (APS) in high-risk patients that are positive for all three recommended tests that detect the presence of antiphospholipid (aPL) antibodies have not been described...
  5. ncbi Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification
    A Ruffatti
    Rheumatology Unit, University of Padua, Padua, Padova, Italy
    J Thromb Haemost 6:1693-6. 2008
    ....
  6. ncbi Invitation to a debate on the serological criteria that define the antiphospholipid syndrome
    M Galli
    J Thromb Haemost 6:399-401. 2008
  7. ncbi Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke
    T Kahles
    Department of Neurology, University Hospital, JW Goethe University Frankfurt, Germany
    Rheumatology (Oxford) 44:1161-5. 2005
    ....
  8. ncbi Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies
    C Chauleur
    Research Team EA2992, Montpellier University 1, Nimes, France
    J Thromb Haemost 8:699-706. 2010
    ..Although this diagnostic classification of APS appeared to be the most sensitive, the APS-associated serological criteria are still debated...
  9. ncbi Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort
    M Petri
    Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland 21205, USA
    Lupus 19:419-23. 2010
    ..Anti-phospholipid antibodies are not associated with atherosclerosis...
  10. ncbi Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
    Monica Galli
    Division of Hematology, Ospedali Riuniti, Bergamo, Italy
    Blood 101:1827-32. 2003
    ..However, to take full advantage of the conclusions provided by the available evidence, there is an urgent need to harmonize investigational methods...
  11. ncbi beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation
    Janine J J Hulstein
    Laboratory for Thrombosis and Haemostasis, Department of Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Blood 110:1483-91. 2007
    ..This mode of action could contribute to the thrombosis and consumptive thrombocytopenia observed in patients with anti-beta(2) GPI antibodies...
  12. ncbi Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5
    Bas de Laat
    Department of Haematology, University Medical Center Utrecht, The Netherlands
    Blood 109:1490-4. 2007
    ..These results are consistent with a model in which aPL antibodies may promote thrombosis by interfering with the anticoagulant activity of AnxA5...
  13. ncbi Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus
    Emily Somers
    Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA
    J Rheumatol 29:2531-6. 2002
    ..To study the relationship between antiphospholipid antibodies (aPL) and the incidence of venous thrombosis (VT) among patients with systemic lupus erythematosus (SLE)...
  14. ncbi IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis
    Bas de Laat
    Department of Haematology, University Medical Centre Utrecht, PO Box 85500, 3584CX Utrecht, The Netherlands
    Blood 105:1540-5. 2005
    ..In conclusion, antibodies directed at domain I (epitope comprising Gly40 and Arg43) have lupus anticoagulant activity and strongly associate with thrombosis...
  15. ncbi Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies
    Giovanni Sanna
    Lupus Research Unit, The Rayne Institute, London, UK
    J Rheumatol 30:985-92. 2003
    ..Neuropsychometric testing was applied by a neuropsychologist. Univariate and multivariate statistical analyses were applied to evaluate the association bewteen NP manifestations, magnetic resonance imaging (MRI) abnormalities, and aPL...
  16. ncbi Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS)
    Carlos J Bidot
    Wallace H Coulter Platelet Laboratory, Division of Hematology Oncology, University of Miami School of Medicine, Miami, Florida 33136, USA
    Am J Hematol 81:391-6. 2006
    ..The difference in APLA may result in opposite clinical manifestations in two disorders...
  17. ncbi Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study
    R Diz-Kucukkaya
    Divisions of Hematology and Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Turkey
    Blood 98:1760-4. 2001
    ..In patients with ITP, the persistent presence of APAs is an important risk factor for the development of APS...
  18. ncbi Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma
    Osnat Bairey
    Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel
    Eur J Haematol 76:384-91. 2006
    ....
  19. ncbi Antiphospholipid antibodies in adults with immune thrombocytopenic purpura
    Carole Pierrot-Deseilligny Despujol
    Centre de Référence National pour la Prise en Charge et la Recherche sur les Cytopénies Auto immunes de l Adulte, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris 12, Creteil, France
    Br J Haematol 142:638-43. 2008
    ..9; 95% CI: 2.3-43.4) or high IgG-aCL level (HR: 7.5; 95% CI; 1.8-31.5). Although the thrombosis rate was low, the significant associations between thrombosis and LA or high aCL level suggest that aPL should be tested at ITP diagnosis...
  20. ncbi Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy
    Eugene R Ahn
    Department of Microbiology Immunology, University of Miami School of Medicine, Miami, FL 33136, USA
    Am J Hematol 78:127-9. 2005
    ..Rituximab induced a lasting remission in a woman suffering from life-threatening hypercoagulable state associated with LA. Her clinical remission was associated with disappearance of LA...
  21. ncbi Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis
    V Pengo
    Clinical Cardiology, Thrombosis Center, University Hospital, 35128 Padova, Italy
    J Thromb Haemost 7:1737-40. 2009
    ..Calculation of cut-off values for each diagnostic step are clearly stated. A final paragraph reports the interpretation of the results in general and in particular situations...
  22. ncbi Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants
    Armando Tripodi
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Dermatology, University and Foundation IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy
    Clin Chem 51:1883-5. 2005
  23. ncbi Kinetics of prothrombin-mediated binding of lupus anticoagulant antibodies to phosphatidylserine-containing phospholipid membranes: an ellipsometric study
    George M Willems
    Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
    Biochemistry 41:14357-63. 2002
    ..The kinetics of adsorption and desorption indicate that divalent binding of LA IgG to prothrombin at the lipid membrane occurs...
  24. ncbi Identification of thrombin antibodies in patients with antiphospholipid syndrome
    Wolfgang Miesbach
    Johann Wolfgang Goethe University, Frankfurt Main Medical Clinic III, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    Ann N Y Acad Sci 1050:250-6. 2005
    ..The sensitivity of the test for anti-thrombin antibodies for the diagnosis of APS was higher than the sensitivity of the anti-prothrombin assay and similar to the sensitivity of the anti-Ser/Pro assay...
  25. ncbi Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study
    Maurizio Turiel
    Department of Cardiology, Istituto Ortopedico Galeazzi, University of Milan, Via Galeazzi 4, 20161 Milan, Italy
    Stroke 36:1490-4. 2005
    ..Because thromboembolic events are frequently observed in primary antiphospholipid syndrome (PAPS), we assessed the risk factors for new thrombotic episodes...
  26. ncbi A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants
    M J A Simmelink
    Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Center, Utrecht, The Netherlands
    J Thromb Haemost 1:740-7. 2003
    ....
  27. ncbi Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants
    J Arnout
    Center for Molecular and Vascular Biology, University of Leuven, Belgium
    Thromb Haemost 86:83-91. 2001
    ..These LA positive monoclonal antibodies may be helpful in further improving the laboratory diagnosis of LA...
  28. ncbi Antiphospholipid antibodies: do we still need to perform anticardiolipin ELISA assays?
    P de Moerloose
    Division of Angiology and Hemostasis, University Hospital, Geneva, Switzerland
    J Thromb Haemost 2:1071-3. 2004
  29. ncbi Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome
    D W Jones
    Kent Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, UK
    Br J Haematol 113:550-2. 2001
    ..4, p = 0.025)...
  30. ncbi Thrombogenic mechanisms of antiphospholipid antibodies
    N L Esmon
    Oklahoma Medical Research Foundation, Department of Biochemistry, University of Oklahoma Health Sciences Center, Howard Hughes Medical Institute, Oklahoma City, USA
    Thromb Haemost 78:79-82. 1997
    ..It is unlikely any single mechanism is responsible for the thrombogenic activity of all APAs associated with thrombosis and this will be a fertile field of investigation for a significant time to come...
  31. ncbi Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications
    J Nojima
    Central Laboratory for Clinical Investigation, Osaka University Hospital, 2 15 Yamadaoka, Suita, Osaka 565 0871, Japan
    Clin Chem 47:1008-15. 2001
    ..Our aim was to clarify the roles in thrombosis of aPL Abs that react with complexes of phospholipids and plasma proteins such as beta(2)-glycoprotein I (beta(2)-GPI), prothrombin, protein C, protein S, and annexin V...
  32. ncbi Antibodies to factor XII associated with lupus anticoagulant
    D W Jones
    Kent Haemophilia Centre, Canterbury Hospitals NHS Trust, United Kingdom
    Thromb Haemost 81:387-90. 1999
    ..These results suggest that FXII antibodies are present in a significant proportion of LA+ patients and may lead to an erroneous diagnosis of FXII deficiency...
  33. ncbi Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces
    J Arnout
    Center for Molecular and Vascular Biology, University of Leuven, Belgium
    Thromb Haemost 79:79-86. 1998
    ..In summary, these experiments indicate that the beta2GPI-dependent LA effect depends on the formation of bivalent beta2GPI-antibody complexes on phospholipid surfaces...
  34. ncbi Thrombophilic dimension of recurrent fetal loss in Indian patients
    Sonal Vora
    National Institute of Immunohaematology ICMR, KEM Hospital, Parel, Mumbai, India
    Blood Coagul Fibrinolysis 19:581-4. 2008
    ....
  35. ncbi Antiphospholipid antibodies: predictive value of laboratory tests
    M Galli
    Division of Haematology, Ospedali Riunlti, Bergamo, Italy
    Thromb Haemost 78:75-8. 1997
    ....
  36. ncbi Effect of anti-beta2glycoprotein I Lupus Anticoagulants on fibrin polymerization and fibrinolysis
    V Pengo
    Department of Clinical and Experimental Medicine, Thrombosis Center, University of Padova School of Medicine, Ex Busonera Hospital, Italy
    Autoimmunity 32:39-44. 2000
    ..These data provide evidence that anti-beta2GPI LA may act as either anticoagulants or procoagulants in different in vitro coagulation tests...
  37. ncbi Autoantibodies against endothelial protein C receptor and the risk of a first deep vein thrombosis
    A Van Hylckama Vlieg
    Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
    J Thromb Haemost 5:1449-54. 2007
    ..Anti-EPCR autoantibodies have been associated with fetal death and myocardial infarction in young women...
  38. ncbi Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis
    Lucie Opatrny
    Division of Clinical Epidemiology, McGill University Hospital Center, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec, Canada
    J Rheumatol 33:2214-21. 2006
    ....
  39. ncbi Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Blood 110:1178-83. 2007
    ..They also suggest that the measurement of aPT and aAnAV antibodies is useful in some selected situations and that there is little role for IgM antibody detection...
  40. ncbi MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension
    Tunde Csepany
    Dept of Neurology, University of Debrecen, Nagyerdei krt 98, 4012, Debrecen, Hungary
    J Neurol 250:1348-54. 2003
    ....
  41. ncbi The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies
    M J Nash
    Haemostasis Research Unit, Department of Haematology, University College London, London, UK
    J Thromb Haemost 2:1077-81. 2004
    ..5 GPLU (normal < 5 GPLU). These data indicate that omission of aCL testing from the clinical investigation of APS could lead to a failure to diagnose the syndrome in a proportion of patients...
  42. ncbi The activated seven lupus anticoagulant assay detects clinically significant antibodies
    Gary W Moore
    Centre for Haemostasis and Thrombosis Haemophilia Reference Centre, St Thomas Hospital, London, England
    Clin Appl Thromb Hemost 14:332-7. 2008
    ....
  43. ncbi Autoantibody explosion in antiphospholipid syndrome
    Yehuda Shoenfeld
    Department of Medicine B, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Israel
    J Autoimmun 30:74-83. 2008
    ..This autoantibody explosion might be important in early identification of the syndrome and its manifestations...
  44. pmc Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus
    C Alessandri
    Cattedra di Reumatologia, Dipartimento di Clinica e Terapia Medica Applicata, Universita La Sapienza, Rome, Italy
    Clin Exp Immunol 140:173-80. 2005
    ..However, the clinical utility of aLBPA detection alone or in combination with aCL and/or abeta(2)-GPI remains to be elucidated in larger and longitudinal studies...
  45. ncbi [Anti-phospholipid antibody (aPL)]
    Moritaka Gotoh
    Department of Internal Medicine, Teikyo University School of Medicine
    Nihon Rinsho 62:687-90. 2004
  46. ncbi Clinical consequences of antiphospholipid antibodies
    R H W M Derksen
    Department of Rheumatology and Clinical Immunology, Room F02 127, University Medical Centre, Heidelberglaan 100, 3584 GA Utrecht, The Netherlands
    Neth J Med 62:273-8. 2004
    ..This paper provides the clinician with guidelines for ordering and interpreting tests for aPL and discusses consequences for treatment if persistently positive tests are found...
  47. pmc Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis
    Jeannine Kassis
    Department of Hematology, Hopital Maisonneuve Rosemont, Universite de Montreal, Montreal, Quebec, Canada
    Thromb Haemost 92:1312-9. 2004
    ..37) for arterial thrombosis compared to those with neither risk factor. In conclusion, APCR phenotype and hyperhomocysteinemia are associated with a higher risk of venous and arterial thrombosis, respectively, in the presence of aPL...
  48. ncbi Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies
    Anne Proven
    Division of Rheumatology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:467-75. 2004
    ..To assess the performance of 4 clotting assays for lupus anticoagulant (LA) detection, to determine the prevalence of LA and anticardiolipin antibodies (aCL), and to correlate LA and aCL prevalence with systemic disease and thrombosis...
  49. ncbi Clinical characteristics of stroke patients with antiphospholipid antibodies
    Hiromi Terashi
    Department of Neurology, Neurological Institute, Tokyo Women s Medical University School of Medicine, Tokyo, Japan
    Cerebrovasc Dis 19:384-90. 2005
    ..Antiphospholipid syndrome is important as a cause of ischemic stroke, although clinical characteristics of the syndrome are not well documented...
  50. ncbi Antiphospholipid antibodies and fetal compromise
    D Ware Branch
    University of Utah Health Sciences Center, LDS Hospital, Room 2B200 SOM, 30 North 1900 East, Salt Lake City, UT 84132, USA
    Thromb Res 114:415-8. 2004
  51. ncbi Clinical significance of anticardiolipin and anti-beta2-glycoprotein I antibodies
    Gerlinde Obermoser
    Department of Dermatology, University Hospital of Innsbruck, Innsbruck, Austria
    Int Arch Allergy Immunol 135:148-53. 2004
    ..The scope of this study was to explore the clinical characteristics of patients with aCl and anti-beta2-gpI antibodies...
  52. ncbi Epileptic seizures in systemic lupus erythematosus
    Simone Appenzeller
    Rheumatology Unit, Department of Internal Medicine, State University of Campinas, Brazil
    Neurology 63:1808-12. 2004
    ..To evaluate the frequency and risk factors of epileptic seizures in a large cohort of patients with systemic lupus erythematosus (SLE)...
  53. ncbi Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vit
    Junzo Nojima
    Laboratory for Clinical Investigation, Osaka University Hospital, 2 15 Yamadaoka, Suita, Osaka 565 0871, Japan
    Thromb Haemost 91:967-76. 2004
    ..These results indicate that anti-CL/beta2-GPI and anti-PS/PT may cooperate to promote platelet activation, which may contribute to the risk of cerebral infarction in patients with SLE...
  54. ncbi Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
    T Hereng
    Department of Internal Medicine, University Hospital of Lille, France
    Lupus 17:11-5. 2008
    ..01). In conclusion, aPL-positive SLE and AIT patients should take aspirin to prevent APS manifestations. Prospective therapeutic trials are needed to confirm aspirin's prophylactic role in such patients...
  55. ncbi [Antiphospholipid syndrome]
    Tatsuya Atsumi
    Department of Medicine II, Hokkaido University Graduate School of Medicine
    Nihon Rinsho 63:484-9. 2005
  56. ncbi [Antiphospholipid syndrome and stroke]
    Yasuhisa Kitagawa
    Department of Neurology, Tokai University Hachioji Hospital
    Rinsho Shinkeigaku 45:852-5. 2005
    ..In SLE patients with stroke, multi-antiphospholipid-protein antibodies was inclined to be present. LA is closely related to ant-PS-PT and aPI and aPS are associated with anti-nuclear antibody and precipitation of atherosclerosis...
  57. ncbi Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients
    T Tarr
    Department of Clinical Immunology, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
    Lupus 16:39-45. 2007
    ..3% of the APS group. These findings indicate that LAC, constant and cumulative presence of aPL and previous thrombosis are positive predictors for the development of thrombotic complication in lupus patients...
  58. ncbi [New insights on disorders of haemostasis in the antiphospholipid syndrome]
    Krystyna Zawilska
    Pracownia Hemostazy Kliniki Hematologii i Chorób Rozrostowych Układu Krwiotwórczego Akademii Medycznej im K Marcinkowskiego w Poznaniu
    Pol Arch Med Wewn 115:491-9. 2006
  59. ncbi Revision of the Sapporo criteria for the antiphospholipid syndrome-- coming to grips with evidence and Thomas Bayes?
    Karl J Lackner
    Thromb Haemost 95:917-9. 2006
  60. ncbi [Antiphospholipid antibodies and antiphospholipid syndrome in juvenile lupus erythematosus]
    Anna M Romicka
    Klinika Reumatologii Wieku Rozwojowego, Instytut Reumatologii Klinika Reumatologii Wieku Rozwojowego
    Pol Arch Med Wewn 115:477-80. 2006
  61. ncbi Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome
    Maria G Tektonidou
    Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
    Arthritis Rheum 50:2569-79. 2004
    ..To evaluate the prevalence, clinical associations, and outcome of antiphospholipid syndrome (APS) nephropathy in patients with systemic lupus erythematosus (SLE) and antiphospholipid antibodies (aPL) and in SLE patients without aPL...
  62. ncbi Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Centre, University of Padova School of Medicine, Ex Busonera Hospital, Via Gattamelata 64, I 35128 Padova, Italy
    Thromb Res 120:127-33. 2007
    ..Nonetheless the high variability of reported data remains a major problem that only a consensus on the part of laboratories and manufacturers to utilize standard, uniform materials and procedures can hope to overcome...
  63. ncbi Significance of antiphospholipid antibodies in lupus nephritis
    Chindarat Natejumnong
    Division of Nephrology, Phramongkutklao Hospital, Bangkok, Thailand
    J Med Assoc Thai 89:S121-8. 2006
    ..Some autoantibodies have been associated with lupus nephritis but the role of antiphospholipid antibodies (APA) is controversial...
  64. ncbi The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome
    Ilan Krause
    Research Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer 52621, Israel
    Immunobiology 210:749-54. 2005
    ..Our data suggest the presence of thrombocytopenia may be a risk factor for cardiac, neurological, articular and cutaneous complications in APS...
  65. ncbi Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies
    Martha E Viveros
    Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Rev Invest Clin 57:563-71. 2005
    ..We investigated the activated protein C resistance (APCR) phenotype and the lupus anticoagulant (LA), activity induced by anti-beta2-glycoprotein-I (anti-beta2GP-I) antibodies...
  66. ncbi Antiphospholipid antibodies
    Douglas A Triplett
    Department of Pathology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Clin Adv Hematol Oncol 1:726-30. 2003
    ..In addition, the currently available methods for laboratory identification of lupus anticoagulants are discussed, as is the laboratory diagnosis of anticardiolipin antibodies...
  67. ncbi Antibody profiles for the diagnosis of antiphospholipid syndrome
    Vittorio Pengo
    Clinical Cardiology, Thrombosis Center, University of Padova School of Medicine, Ex Busonera Hospital, Via Gattamelata 64, 1 35128 Padova, Italy
    Thromb Haemost 93:1147-52. 2005
    ..As compared to a single test, the analysis of a complete antiphospholipid antibody profile can better determine patients at risk...
  68. ncbi Anti-oxLDL antibodies--marker for arterial thromboses in antiphospholipid syndrome?
    Mirjana Becarevic
    Institute for Medical Biochemistry, Clinical Center of Serbia, Belgrade
    Clin Lab 51:279-83. 2005
    ..25, p < 0.05), which was not dependent on diagnosis. These preliminary observations have to be confirmed in a larger study...
  69. ncbi Hyperhomocysteinemia relates to the subtype of antiphospholipid antibodies in non-SLE patients
    Wei Hsi Chen
    Stroke Biology Research Laboratory, Department of Neurology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
    Clin Appl Thromb Hemost 13:398-403. 2007
    ..The role of vasculopathic or prothrombotic autoantibody generation in response to specific pathological change such as hyperhomocysteinemia warrants further investigation...
  70. ncbi Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?
    José A Gómez-Puerta
    Lupus Research Unit, Rayne Institute, St Thomas Hospital, London, United Kingdom
    Medicine (Baltimore) 84:225-30. 2005
    ..Only 3 patients developed anti-dsDNA antibodies. The presence of a positive Coombs test might be a marker for the development of SLE in patients with primary APS...
  71. ncbi [The antiphospholipid syndrome, an update]
    J E Alonso Santor
    Servicio de Medicina Interna, Hospital Universitario Rio Hortega, Valladolid, Spain
    An Med Interna 24:242-8. 2007
    ..It is very important to evaluate in this setting additional, coincident prothrombotic risk factors...
  72. pmc The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-beta2-glycoprotein I antibodies
    C Neville
    Division of Clinical Epidemiology, Montreal General Hospital, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    Rheumatology (Oxford) 45:1116-20. 2006
    ....
  73. ncbi Antiphospholipid antibodies in young adults with stroke
    Robin L Brey
    University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284 7883, USA
    J Thromb Thrombolysis 20:105-12. 2005
    ..Antiphospholipid antibodies have been associated with a clinical syndrome consisting thrombosis and recurrent, unexplained fetal loss...
  74. ncbi [Laboratory diagnosis of antiphospholipid syndrome]
    L Darnige
    Service d Hematologie Biologique, Hopital Europeen Georges Pompidou, 20 40, rue Leblanc, 75908 Paris Cedex 15, France
    Rev Med Interne 27:296-301. 2006
    ..e. lupus anticoagulant and/or anticardiolipin antibodies. This review focuses on the methods for antiphospholipid antibodies detection and their clinical usefulness...
  75. ncbi [Antiphospholipid syndrome]
    C Specker
    Klinik für Rheumatologie and Klinische Immunologie, Katholisches Krankenhaus St Josef, Zentrum für Innere Medizin der Kliniken Essen Süd, Essen
    Z Rheumatol 66:41-50; quiz 51-2. 2007
    ....
  76. ncbi beta 2 Glycoprotein I--a key player in the antiphospholipid syndrome
    Bianca C H Lutters
    Department of Haematology, University Medical Center, Utrecht, The Netherlands
    Isr Med Assoc J 4:958-62. 2002
  77. pmc Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies
    Carolyn Neville
    Division of Clinical Epidemiology, The Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada
    Thromb Haemost 90:108-15. 2003
    ..5 [0.93-2.3] for ATE and 1.7 [1.1-2.5] for VTE. These results indicate that increased titres of aCL and multiple aPL were associated with an increased risk of a previous thrombotic event...
  78. ncbi Anti-beta2-glycoprotein I antibodies and ischemic stroke in a 20-month-old boy
    Eustathia Katsarou
    Department of Neurology, Panagiotis and Aglaia Kyriakou Children s Hospital, Athens, 11527 Greece
    Pediatrics 112:188-90. 2003
    ..This case supports the recommendation of others to search for these antibodies in the presence of strong clinical suspicion of antiphospholipid syndrome, when anticardiolipin antibodies and lupus anticoagulant tests are negative...
  79. ncbi [Clinical case of the month. Report of a case of antiphospholipid syndrome]
    A Fumal
    Service de Neurologie,
    Rev Med Liege 56:480-3. 2001
    ..We reviewed the literature dedicated to the prothrombotic events linked to the presence of these antiphospholipid antibodies: the lupus anticoagulant and the anticardiolipin antibodies...
  80. ncbi The concomitant presence of lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein i antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients
    Laura Gennari
    Br J Haematol 121:527-9. 2003
  81. ncbi [Anti-phospholipid syndrome nephropathy]
    Dominique Nochy
    Service d Anatomie Pathologique, Hopital Europeen Georges Pompidou, 20, rue Leblanc, 75908 Paris Cedex15
    Ann Med Interne (Paris) 154:51-8. 2003
    ..We showed the following..
  82. ncbi Antiphospholipid antibodies and the risk of thromboembolic events in valvular heart disease
    Hélène G Bulckaen
    Service de médecine interne et gériatrie, hôpital gériatrique Les Bateliers, Centre Hospitalier Regional et Universitaire de Lille, 59037 Lille, France
    Mayo Clin Proc 78:294-8. 2003
    ..To investigate the role of antiphospholipid antibodies (aPLs) in subsequent thromboembolic events and mortality in a prospective follow-up of 89 patients with severe, nonspecific valvular heart disease...
  83. ncbi Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis
    Jacek Musial
    Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
    J Rheumatol 30:723-30. 2003
    ....
  84. ncbi The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus
    M L Bertolaccini
    Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital, London, UK
    J Rheumatol 28:2637-43. 2001
    ..IgA aPT and aPS/PT are not present in patients with SLE, therefore there is no need to test for these antibodies...
  85. ncbi Antiphospholipid antibodies and infertility
    May Backos
    Department of Reproductive Science and Medicine, Imperial College School of Medicine at St Mary s Hospital, London W2 1NY, UK
    Hum Fertil (Camb) 5:30-4. 2002
    ..Hence routine screening for aPL among women undergoing IVF-ET is not warranted and therapeutic interventions should be used only in well designed randomized controlled trials...
  86. pmc Detection of 'antiphospholipid' antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)-glycoprotein I and prothrombin
    Y Sheng
    Department of Medicine, St George Hospital, Kogarah and the University of New South Wales, Sydney, New South Wales, Australia
    Clin Exp Immunol 124:502-8. 2001
    ..All MoAbs binding beta(2)GPI showed inhibition of thrombin generation, while MoAbs binding domain I of beta(2)GPI had more LA effect...
  87. ncbi The antiphospholipid syndrome and infection
    G N Dalekos
    Larisa Medical School, University of Thessaly, 22 Papakiriazi Str, 412 22, Larisa, Greece. dalekos@ med.uth.gr
    Curr Rheumatol Rep 3:277-85. 2001
    ..Therefore, it may be possible to prevent this devastating evolution if the infectious process is promptly recognized and exhaustively treated...
  88. ncbi [Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population]
    I Marai
    Department of Medicine B and Research Unit of Autoimmune Diseases, Chaim Sheba Medical Center (Affiliated to Tel-Aviv University, Israel
    Harefuah 140:495-500, 565. 2001
    ..Overall, the patients require therapy with anticoagulant treatment and antiaggregant drugs. The clinical manifestations were similar in Israeli and non-Israeli patients...
  89. ncbi [Antiphospholipid antibodies and neurological disorders. Types and mechanisms]
    C Viñets
    Departamento de Medicina, Universidad de Alicante, Espana
    Rev Neurol 24:1224-8. 1996
    ..Their role as a probable risk factor for thrombosis in the general population is also discussed. For these reasons, we decided to review the basic biology of the AAFL and the aspects related to neurological disorders...
  90. ncbi Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis?
    Eun Young Lee
    Division of Allergy and Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388 1 Pungnap dong, Songpa Gu, Seoul 138 736, South Korea
    Thromb Res 111:29-32. 2003
    ..To investigate whether the anti-beta(2)-glycoprotein I (anti-beta(2)GPI) antibody may provide additional information in patients with thrombosis in conjunction with the lupus anticoagulant (LAC) or anticardiolipin (aCL) antibody...
  91. ncbi The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus
    Jan Leendert P Brouwer
    Division of Haemostasis, Thrombosis and Rheology, Department of Hematology, University Hospital Groningen The Netherlands
    Blood 104:143-8. 2004
    ..In conclusion, factor V Leiden and the prothrombin mutation contribute to the risk of VTE in patients with SLE, and potentiate this risk when one of these thrombophilic defects are combined with LA and/or ACAs...
  92. ncbi Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus
    L M A Campos
    Paediatric Rheumatology Unit, Children s Institute, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, Brazil
    Lupus 12:820-6. 2003
    ..A negative association was observed between APS and the presence of anti-Ro antibodies...
  93. ncbi Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I
    J Arnout
    Center for Molecular and Vascular Biology, University of Leuven, Belgium
    Thromb Haemost 81:929-34. 1999
    ....
  94. ncbi [Thrombophilia, preeclampsia and other pregnancy complications]
    Niksa Vucić
    Department of Hematology and Blood Coagulability Disorders, University Department of Medicine, Sveti Duh General Hospital, Zagreb, Croatia
    Acta Med Croatica 63:297-305. 2009
    ..The necessity of anticoagulation therapy in women with inherited or acquired thrombophilia is biologically plausible; nevertheless, optimum management in such cases remains unknown...
  95. ncbi [Antiphospholipid syndrome and antiphospholipid antibodies as a risk factors of ischaemic heart disease and myocardial infarction in patients with systemic lupus erythematosus]
    Lidia Ostanek
    Klinika Reumatologii PAM w Szczecinie
    Pol Arch Med Wewn 115:407-13. 2006
    ..The risk factors of ischemic heart disease and myocardial infarction in SLE patients significantly differ from the ones in general population...
  96. ncbi The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus
    Donna Dizon-Townson
    National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network, Bethesda, Maryland, USA
    Obstet Gynecol 106:517-24. 2005
    ....
  97. ncbi Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus
    Adriana Danowski
    Rheumatology Department, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore MD 21205, USA
    J Rheumatol 36:1195-9. 2009
    ..In most series, only a minority of patients with antiphospholipid antibodies develop a clinical manifestation...
  98. ncbi Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients
    Reed E Drews
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
    Clin Chest Med 24:607-22. 2003
    ..Because of its anticoagulant effect, however, drotrecogin alfa may induce bleeding. Guidelines for drotrecogin alfa use must take into account bleeding risks...
  99. ncbi Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model
    David L McGlasson
    Clinical Research Squadron MSRL, Lackland AFB, TX 78236 5300, USA
    Clin Lab Sci 20:99-105. 2007
    ..Establishment of a dose-response relationship is an important first step in determining if the NZW rabbit is a suitable model to study both cutaneous and systemic effects of the venom...
  100. ncbi Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies
    M Galli
    Department of Haematology, Ospedali Riuniti, Bergamo, Italy
    Thromb Haemost 77:486-91. 1997
    ..These findings suggest that anti-prothrombin antibodies resemble aCL antibodies with respect to the behaviour in "in vitro" coagulation reactions and underline the wide heterogeneity of antiphospholipid antibodies...
  101. ncbi Diagnostic dilemma: unrelenting Fever, cytopenia, and systemic inflammation in a 20-year-old patient
    Neeraj Agnihotri
    Division of Hematology and Oncology, Maimonides Medical Center, Brooklyn, NY
    Clin Lymphoma Myeloma Leuk 10:E36. 2010
    ..Such a typical case of HLH is extremely rare. Clinicians should maintain a high degree of suspicion to rule out HLH. Our case adds to the literature on this rare disease and will help in understanding the disease better...

Research Grants27

  1. NOVEL BIOMARKERS FOR MECHANISTIC DIAGNOSIS OF THE ANTIPHOSPHOLIPID SYNDROME
    JACOB RAND; Fiscal Year: 2010
    ....
  2. Epidemiologic Study of Placental Abruption
    Cande Ananth; Fiscal Year: 2006
    ..It will also add substantial new evidence for associations of several genetic thrombophilias and abruption risk. ..
  3. Prothrombin Gene Variation and the Risk of SLE and CHD
    M Ilyas Kamboh; Fiscal Year: 2010
    ....
  4. ANTICARDIOLIPIN ANTIBODIES AND OXIDIZED PHOSPHOLIPIDS
    Joseph Witztum; Fiscal Year: 2004
    ..g. aggressive anti-inflammatory and/or antioxidant interventions). ..
  5. ANTIPHOSPHOLIPID ANTIBODIES IN THROMBOSIS
    Reginald Chukwuocha; Fiscal Year: 2000
    ..The results of these studies will help delineate which APAs are likely to cause thrombosis and may lead to a better prediction of thrombogenic events in APS patients. ..
  6. ANTICARDIOLIPIN ANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME
    Pojen Chen; Fiscal Year: 2007
    ..abstract_text> ..
  7. Safety of Estrogen in Lupus Erythematosus
    Jill Buyon; Fiscal Year: 2004
    ..abstract_text> ..
  8. Analysis of Apolipoprotein H in Lupus
    M Kamboh; Fiscal Year: 2006
    ..Aim 5) perform in vitro mutagenesis and expression studies to express different apoH allelic-isoforms to evaluate isoform-specific inhibition of LDL oxidation. ..
  9. Brain Connections
    Michelle Petri; Fiscal Year: 2006
    ..abstract_text> ..
  10. Revision of ACR Classification Criteria for Systemic Lupus Erythematosus
    Michelle Petri; Fiscal Year: 2007
    ..This project will lead to updated, validated SLE classification criteria that can be immediately used by both industry and academic clinical trials. ..
  11. AUTOIMMUNE MECHANISMS OF THROMBOSIS
    Robert Roubey; Fiscal Year: 2004
    ..These data will be useful in focusing future research efforts on specific pathways of antibody-mediated monocyte activation and hypercoagulability and in designing new therapeutic strategies...
  12. SPORADIC MECHANISM OF THE ANTIPHOSPHOLIPID SYNDROME
    Joan Merrill; Fiscal Year: 2001
    ..Therefore, possible modulation by sex-hormones of interactions between these proteins will be addressed in this application. ..
  13. PREDICTORS OF NEUROPSYCHIATRIC SLE
    ROBIN BREY; Fiscal Year: 2004
    ..The information gained will bridge important gaps in our knowledge about NS involvement in SLE and will lead to new hypothesis-driven studies of etiopathogenesis and treatment. ..
  14. Cognitive Function in SLE (COGNITION)
    Robin L Brey; Fiscal Year: 2010
    ..The information that will be gained from this study is essential for the successful discovery of biological processes that impact on cognitive function in SLE that could be potentially amenable to disease-reversing therapies. ..
  15. TFPI ALPHA AND TFPI BETA
    George Broze; Fiscal Year: 2009
    ....
  16. Libman-Sacks Endocarditis and NPSLE
    Carlos Roldan; Fiscal Year: 2009
    ....
  17. Procoagulants in Aging CARDIA Participants
    David Green; Fiscal Year: 2009
    ....
  18. HUMAN TISSUE FACTOR AND ITS PLASMA INHIBITOR
    George Broze; Fiscal Year: 2001
    ....
  19. Polymorphisms of Antiphospholipid Protein Antigens
    Joan Merrill; Fiscal Year: 2005
    ..Additionally, the study of differences in interactions between these coagulation proteins conferred by common, inherited polymorphisms will have intrinsic value, not limited to the antiphospholipid syndrome. ..
  20. AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM
    Alexandra Levine; Fiscal Year: 2005
    ..The expertise of our labs and experience will be available to the AMC, which will be considered of the highest priority for our Group. ..
  21. Cognitive dysfunction in neuropsychiatric-SLE
    Michael Lockshin; Fiscal Year: 2002
    ..Successful completion of this research will redefine the pathogenesis of cognitive dysfunction and suggest therapeutic targets for intervention...
  22. ANTI-PHOSPHOLIPID ANTIBODIES AND THE PROTEIN C SYSTEM
    NAOMI ESMON; Fiscal Year: 2006
    ....
  23. Immune Thrombocytopenia and Low-Level Mercury Exposure
    Jodi Segal; Fiscal Year: 2006
    ..Segal with the necessary support for successful completion [unreadable] [unreadable] [unreadable]..
  24. MIDCAREER INVESTIGATOR AWARD IN PATIENT-ORIENTED RESEAR
    ROBIN BREY; Fiscal Year: 2006
    ..Much will be learned about the relative importance of genetic factors and autoantibodies on vascular disease risk in SLE that is likely to apply to other populations also at increased risk for cerebral ischemia and vascular dementia. ..
  25. Stroke:Role of aPL, hemostatic markers, and telestroke
    Steven Levine; Fiscal Year: 2006
    ....